# Intranasal Oxytocin and Learning in Autism

> **NCT01417026** · PHASE2 · COMPLETED · sponsor: **Robert Schultz** · enrollment: 36 (actual)

## Conditions studied

- Autism Spectrum Disorders

## Interventions

- **DRUG:** Intranasal Oxytocin (Trade name: Syntocinon)

## Key facts

- **NCT ID:** NCT01417026
- **Lead sponsor:** Robert Schultz
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2015-04
- **Final completion:** 2015-04
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2017-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01417026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01417026, "Intranasal Oxytocin and Learning in Autism". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01417026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*